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Intravenous Busulfan is a common conditioning agent for
children undergoing HCT. A potential adverse effect of
Busulfan is seizures thus anti-convulsant prophylaxis is
standard. Phenytoin is no longer preferred given its potent
inhibition of cytochrome P450 hepatic enzymes and benzo-
diazepenes also have signiﬁcant side effects that may
prohibit use. One promising alternative is Levetiracetam,
a second-generation antiepileptic with lower side effect
proﬁle and limited drug interactions including Busulfan. We
evaluated the incidence, safety, and efﬁcacy of Levetiracetam
for short-term anti-seizure prophylaxis in pediatric patients
receiving Busulfan as part of HCT conditioning.
Retrospective chart review was done on patients who
received Busulfan prior to HCT from 2007 to 2012. A total of
95 patients with a malignant or non-malignant diseases, and
autologous or allogeneic donors were included. First line
anti-convulsant therapy was Lorazepam (0.2mg/kg IV/PO
every 6 hours). Those patients who had documented or new
adverse reactions to Lorazepam, who were already taking
Levetiracetam, or who had increased baseline risk factors for
seizures, received alternative prophylaxis with Levetir-
acetam (10-15mg/kg IV/PO every 6 hours).
Of the 95 patients who received Busulfan-based condi-
tioning, 33 (35%) received Levetiracetam instead of institu-
tional standard Lorazepam. Thirteen of the 33 patients (30%)
were either previously on Levetiracetam due to a prior
seizure or received it preemptively due to increased risk of
seizures. Twenty-three of these 33 patients (70%) were
switched to Levetiracetam due to prior (n¼10) or develop-
ment of new (n¼13) adverse reaction to Lorazepam. Leve-
tiracetam was extremely well tolerated with no adverse
events. There were no Busulfan-induced seizures or neuro-
toxicity in either cohort.
Our ﬁndings indicate that one-third of analyzed patients
required Levetiracetam instead of the institutional standard
of Lorazepam for anti-convulsant prophylaxis during
Busulfan administration. Overall, Levetiracetam was efﬁca-
cious in preventing Busulfan-induced seizures with no
documented side effects, whereas Lorazepamwas not as well
tolerated. Notably, a signiﬁcant number of patients devel-
oped adverse reactions to Lorazepam mid-chemotherapy
creating interruptive and unpleasant side effects, the most
common being over-sedation, irritability and hyperactivity.
Practically and economically, Levetiracetam is also attractive
given its less frequent dosing and available low-cost generic
formulation.
Current practice is to use benzodiazepines to prevent
Busulfan-induced seizures. Our ﬁndings substantiate earlydata showing that not only is Levetiracetam safe, effective,
and feasible in preventing Busulfan-induced seizures during
pediatric HCT, but also may actually be favorable due to
lower side effect proﬁle and ease of administration.291
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Introduction: Toxicity associated with the hematopoietic
stem cell transplant (HSCT) process commonly results in
a need for critical care resources. Identifying biomarkers
associated with critical illness in HSCT patients may improve
outcomes. Brain natriuretic peptide (BNP) has become
a useful marker of cardiopulmonary disease inmany settings.
The value of BNP levels early in the HSCT process in children
is largely unknown.
Hypothesis: Children with elevated BNP levels during the
ﬁrst 14 days after HSCT will be at higher risk for toxicity and
more likely to require critical care resources during the ﬁrst
100 days after HSCT.
Methods: A multicenter, prospective study recruited pedi-
atric allogeneic HSCT patients from 5 tertiary care centers.
BNP levels were assessed at the start of conditioning, at Day-
1, and at Days +1, +7, +14, +21, +28, and +100 after HSCT.
Patients were followed for 100 days after HSCT. Outcome
variables included the need for inotropic support, supple-
mental oxygen, PICU admission and survival. Odds ratios
were determined to assess the relationship of elevated BNP
levels with these outcomes. An elevated BNP level was
deﬁned a priori as > 100 pg/mL.
Results: Fifty one patients were enrolled. The median age
was 12 years (IQR 6-15). There were 29 males. Forty patients
(78%) were transplanted for malignant diseases. Thirty eight
of the 51 patients (75%) had at least 1 BNP level> 100 within
14 days of transplant. The median BNP levels were 21, 28.5,
65, 56, 105, 55, 36 and 24 pg/mL at baseline, Day-1, +1, +7,
+14, +21, +28 and +100 of HSCT respectively. A BNP level >
100 was associated with a need for oxygen (P ¼ .003) and
PICU admission (P ¼ .02), but not inotropic support. Overall,
23 of the 51 patients (45%) required oxygen. Of these 23, all
but one (96%) had at least one BNP level > 100 during the
ﬁrst 14 days post HSCT. In contrast, only 16 of the 28 patients
(57%) who did not require oxygen had a BNP level > 100
during that time frame (Odds ratio 16.5, 95% CI (1.9 e 140.1)).
Nineteen of the 51 patients (37%) required admission to the
PICU. Of these 19, 18 patients (95%) had at least one BNP >
100 within the ﬁrst 14 days of HSCT. In contrast, only 20 of
